-
Protein glycosylation in cardiovascular health and disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-18 John C. Chatham, Rakesh P. Patel
-
Extracellular Kir2.1C122Y Mutant Upsets Kir2.1-PIP2 Bonds and Is Arrhythmogenic in Andersen-Tawil Syndrome Circ. Res. (IF 20.1) Pub Date : 2024-03-18 Francisco M. Cruz, Álvaro Macías, Ana I. Moreno-Manuel, Lilian K. Gutiérrez, María Linarejos Vera-Pedrosa, Isabel Martínez-Carrascoso, Patricia Sánchez Pérez, Juan Manuel Ruiz Robles, Francisco J. Bermúdez-Jiménez, Aitor Díaz-Agustín, Fernando Martínez de Benito, Salvador Arias-Santiago, Aitana Braza-Boils, Mercedes Martín-Martínez, Marta Gutierrez-Rodríguez, Juan A. Bernal, Esther Zorio, Juan Jiménez-Jaimez
BACKGROUND:Andersen-Tawil syndrome type 1 is a rare heritable disease caused by mutations in the gene coding the strong inwardly rectifying K+ channel Kir2.1. The extracellular Cys (cysteine)122-to-Cys154 disulfide bond in the channel structure is crucial for proper folding but has not been associated with correct channel function at the membrane. We evaluated whether a human mutation at the Cys122-to-Cys154
-
Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth Circulation (IF 37.8) Pub Date : 2024-03-15 Tal Caller, Itai Rotem, Olga Shaihov-Teper, Daria Lendengolts, Yeshai Schary, Ruty Shai, Efrat Glick-Saar, Dan Dominissini, Menachem Motiei, Idan Katzir, Rachela Popovtzer, Merav Nahmoud, Alex Boomgarden, Crislyn D’Souza-Schorey, Nili Naftali-Shani, Jonathan Leor
BACKGROUND:Myocardial infarction (MI) and heart failure are associated with an increased incidence of cancer. However, the mechanism is complex and unclear. Here, we aimed to test our hypothesis that cardiac small extracellular vesicles (sEVs), particularly cardiac mesenchymal stromal cell–derived sEVs (cMSC-sEVs), contribute to the link between post-MI left ventricular dysfunction (LVD) and cancer
-
Circadian Mechanisms in Cardiovascular and Cerebrovascular Disease Circ. Res. (IF 20.1) Pub Date : 2024-03-14 Eng H. Lo, Frank M. Faraci
All living organisms on Earth demonstrate rhythms in biological function, which are approximately tied to the 24-hour cycle of a single day and night. The term diurnal is commonly used to describe events that occur during the day. For example, a diurnal species is the one that is mainly active during the daylight. In contrast, the term circadian refers to a rhythm that has a period of ≈24 hours but
-
Circadian Clock and Hypoxia Circ. Res. (IF 20.1) Pub Date : 2024-03-14 Francesca Sartor, Borja Ferrero-Bordera, Jeffrey Haspel, Markus Sperandio, Paul M. Holloway, Martha Merrow
The timing of life on Earth is remarkable: between individuals of the same species, a highly similar temporal pattern is observed, with shared periods of activity and inactivity each day. At the individual level, this means that over the course of a single day, a person alternates between two states. They are either upright, active, and communicative or they lie down in a state of (un)consciousness
-
Circadian and Diurnal Regulation of Cerebral Blood Flow Circ. Res. (IF 20.1) Pub Date : 2024-03-14 Alastair J.S. Webb, Elizabeth B. Klerman, Emiri T. Mandeville
Circadian and diurnal variation in cerebral blood flow directly contributes to the diurnal variation in the risk of stroke, either through factors that trigger stroke or due to impaired compensatory mechanisms. Cerebral blood flow results from the integration of systemic hemodynamics, including heart rate, cardiac output, and blood pressure, with cerebrovascular regulatory mechanisms, including cerebrovascular
-
Characterizing the immune response to myocardial infarction in pigs Basic Res. Cardiol. (IF 9.5) Pub Date : 2024-03-15 Florian Schnitter, Franziska Stangl, Elisabeth Noeske, Maya Bille, Anja Stadtmüller, Niklas Vogt, Florian Sicklinger, Florian Leuschner, Anna Frey, Laura Schreiber, Stefan Frantz, Niklas Beyersdorf, Gustavo Ramos, Nadine Gladow, Ulrich Hofmann
-
Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-16 Frederick M. Lang, Sergio Teruya, Ariel Weinsaft, Margaret Cuomo, Alfonsina Mirabal Santos, Ani Nalbandian, Dimitrios Bampatsias, Mathew S. Maurer
AimsDespite their potential, sodium–glucose cotransporter 2 inhibitors (SGLT2i) have not been well‐studied in transthyretin amyloid cardiomyopathy (ATTR‐CM) as randomized trials have excluded patients with this morbid disease. We performed a retrospective study assessing the short‐term efficacy and safety of SGLT2i in ATTR‐CM.Methods and resultsWe screened consecutive patients seen at a tertiary care
-
Imaging cAMP nanodomains in human iPSC-derived cardiomyocytes Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-15 Camille Charrière
In this Tools of the Trade article, Charrière describes the FluoStep FRET-based biosensor used for high-resolution imaging of cAMP nanodomains that are involved in intracellular signalling in cardiomyocytes.
-
Novel cardiovascular therapeutics and the risk of financial toxicity Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-14 Alexander H. Gunn, Akshay Pendyal
Novel cardiovascular therapeutics have the potential to improve health outcomes, but financial toxicity from high out-of-pocket costs can limit the reach of these medications and worsen existing health disparities. Understanding the phenomenon of financial toxicity in treating cardiovascular disease is crucial to achieving health equity.
-
Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association Circulation (IF 37.8) Pub Date : 2024-03-11 Salim S. Hayek, Vlad G. Zaha, Carmel Bogle, Anita Deswal, Amelia Langston, Seth Rotz, Alexi Vasbinder, Eric Yang, Tochukwu Okwuosa, on behalf of the American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine, and the Council on Cardiovascular and Stroke Nursing
Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking. This American Heart Association scientific statement summarizes the data on transplantation-related complications and provides guidance
-
Anderson–Fabry disease management: role of the cardiologist Eur. Heart J. (IF 39.3) Pub Date : 2024-03-15 Maurizio Pieroni, Mehdi Namdar, Iacopo Olivotto, Robert J Desnick
Anderson–Fabry disease (AFD) is a lysosomal storage disorder characterized by glycolipid accumulation in cardiac cells, associated with a peculiar form of hypertrophic cardiomyopathy (HCM). Up to 1% of patients with a diagnosis of HCM indeed have AFD. With the availability of targeted therapies for sarcomeric HCM and its genocopies, a timely differential diagnosis is essential. Specifically, the therapeutic
-
Recombinant human soluble domain of CD39L3 and ticagrelor: cardioprotective effects in experimental myocardial infarction Eur. Heart J. (IF 39.3) Pub Date : 2024-03-15 Gemma Vilahur, Monika Radike, Pablo Sutelman, Soumaya Ben-Aicha, Manuel Gutiérrez, Laura Casaní, Daniel Hovdal, Emily L Ongstad, Anders Gabrielsen, Alberto Hidalgo, Ola Fjellström, Leif Carlsson, Lina Badimon
Background and Aims The ecto–nucleoside triphosphate diphosphohydrolases of the CD39 family degrade ATP and ADP into AMP, which is converted into adenosine by the extracellular CD73/ecto-5-nucleotidase. This pathway has been explored in antithrombotic treatments but little in myocardial protection. We have investigated whether the administration of solCD39L3 (AZD3366) confers additional cardioprotection
-
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-15 Alexander Peikert, Muthiah Vaduganathan, Brian L. Claggett, Ian J. Kulac, Alberto Foà, Akshay S. Desai, Pardeep S. Jhund, Jaclyn Carberry, Carolyn S.P. Lam, Mikhail N. Kosiborod, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Adrian F. Hernandez, Sanjiv J. Shah, Lars Køber, Piotr Ponikowski, Marc S. Sabatine, Magnus Petersson, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon
-
Characterization of anthracycline-induced cardiotoxicity by diffusion tensor magnetic resonance imaging Basic Res. Cardiol. (IF 9.5) Pub Date : 2024-03-14
Abstract Anthracyclines are highly potent anti-cancer drugs, but their clinical use is limited by severe cardiotoxic side effects. The impact of anthracycline-induced cardiotoxicity (AIC) on left ventricular (LV) microarchitecture and diffusion properties remains unknown. This study sought to characterize AIC by cardiovascular magnetic resonance diffusion tensor imaging (DTI). Mice were treated with
-
Modelling pre-eclampsia and its cardiovascular effects Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-13 Sol Olivera, Delyth Graham
In this Tools of the Trade article, Olivera describes a rat model of pre-elampsia that has been instrumental for investigating potential long-term cardiovascular effects in offspring.
-
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials Circulation (IF 37.8) Pub Date : 2024-03-11 Prakriti Gaba, Joseph F. Sabik, Sabina A. Murphy, Andrea Bellavia, Patrick T. O’Gara, Peter K. Smith, Patrick W. Serruys, A. Pieter Kappetein, Seung-Jung Park, Duk-Woo Park, Evald H. Christiansen, Niels R. Holm, Per H. Nielsen, Marc S. Sabatine, Gregg W. Stone, Brian A. Bergmark
BACKGROUND:Diabetes may be associated with differential outcomes in patients undergoing left main coronary revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). The aim of this study was to investigate outcomes in patients with left main disease with and without diabetes undergoing PCI versus CABG.METHODS:Individual patient data were pooled from
-
Efficacy and safety of the Aria pulmonary endovascular device in pulmonary hypertension Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-14 Christian Gerges, Karl Vollmers, Nika Skoro‐Sajer, Varius Dannenberg, Valerie Hartig, Marc R. Pritzker, John Scandurra, E. Kenneth Weir, Irene M. Lang
-
An epigenome editing approach induces durable silencing of Pcsk9 Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-13 Irene Fernández-Ruiz
A new approach to modify the epigenome can lead to durable silencing of Pcsk9 in mice, thereby reducing plasma LDL-cholesterol levels, according to a study published in Nature.
-
Tackling inflammation in atherosclerosis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-12 Mohsen Shoaran, Pasquale Maffia
Shoaran and Maffia recount how our understanding of the role of inflammation in atherosclerosis has evolved and highlight the study by Göran Hansson and colleagues that provided the first hint of the involvement of the adaptive immune response in atherosclerosis.
-
Pathophysiology and clinical relevance of atrial myopathy Basic Res. Cardiol. (IF 9.5) Pub Date : 2024-03-12 Michiel R. L. Tubeeckx, Gilles W. De Keulenaer, Hein Heidbuchel, Vincent F. M. Segers
-
Correction to: 2023 Scientific Sessions Abstract 18987 Circulation (IF 37.8) Pub Date : 2024-03-11
In the 2023 Scientific Sessions abstract by Umrani et al, “Abstract 18987: A 10-Year Contemporary Analysis of Outcomes of Patients With Amyloidosis and VT Underdoing Ventricular Tachycardia (VT) Ablation,” which published on November 6, 2023 (Circulation. 2023;148:A18987. DOI: 10.1161/circ.148.suppl_1.18987), a correction is needed. In the author byline, author “Yaser Khallid” has been updated to read
-
The salt paradox in heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-12 Zachary L. Cox, Jeffrey M. Testani
-
Sodium–glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-12 Nathanael Wood, Sam Straw, Chew W. Cheng, Yu Hirata, Marcelo G. Pereira, Harrison Gallagher, Stuart Egginton, Wataru Ogawa, Stephen B. Wheatcroft, Klaus K. Witte, Lee D. Roberts, T. Scott Bowen
-
Antiarrhythmic Drug Therapy: Where Do We Go From Here? Circulation (IF 37.8) Pub Date : 2024-03-11 Peter R. Kowey, Gerald V. Naccarelli
Most sufferers with heart disease cannot be cured. The purpose of intelligent care is the prolongation of life, the diminution of suffering, and the increase in the mental and physical efficiency of the patient. — Samuel Levine, Clinical Heart Disease Fourth Edition, Saunders, 1951 Antiarrhythmic drugs have been and will remain the mainstay of the chronic therapy of patients who have cardiac arrhythmias
-
Correction to: Development and Validation of the American Heart Association’s PREVENT Equations Circulation (IF 37.8) Pub Date : 2024-03-11
In the article by Khan et al, “Development and Validation of the American Heart Association’s PREVENT Equations,” which appeared in the February 6, 2024, issue of the journal (Circulation. 2024;149:430–449. DOI: 10.1161/CIRCULATIONAHA.123.067626), a correction is needed. On page 433, the year range in the following sentence was updated from 2015–2020 to 2015–2019, to read, “The SDI was calculated at
-
Correction to: 2023 Scientific Sessions Abstract 18918 Circulation (IF 37.8) Pub Date : 2024-03-11
In the 2023 Scientific Sessions abstract by Umrani et al, “Abstract 18918: Outcomes of Patients With Transcatheter Aortic Valve Replacement (TAVR) and Cardiac Resynchronization Therapy (CRT): A Retrospective Analysis,” which published on November 6, 2023 (Circulation. 2023;148:A18918. DOI: 10.1161/circ.148.suppl_1.18918), a correction is needed. In the author byline, Yaser Khalid has been added as
-
Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2024-03-11 Adam B. Greenbaum MD, Hiroki A. Ueyama MD, Patrick T. Gleason MD, Jaffar M. Khan PhD BM BCh, Christopher G. Bruce MB ChB, Rim N. Halaby MD, Toby Rogers PhD BM BCh, George S. Hanzel MD, Joe X. Xie MD, Isida Byku MD, Robert A. Guyton MD, Kendra J. Grubb MD, John C. Lisko MD, Nikoloz Shekiladze MD, Errol K. Inci MD, Elizabeth A. Grier MD, Gaetano Paone MD, James M. McCabe MD, Robert J. Lederman MD, Vasilis
Left ventricular outflow tract (LVOT) obstruction is a source of morbidity in hypertrophic cardiomyopathy (HCM) and a life-threatening complication of transcatheter mitral valve replacement (TMVR) and transcatheter aortic valve replacement (TAVR). Available surgical and transcatheter approaches are limited by high surgical risk, unsuitable septal perforators, and heart block requiring permanent pacemakers
-
Implications of tricuspid regurgitation and right ventricular volume overload in patients with heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-11 Karl‐Patrik Kresoja, Sebastian Rosch, Anne Rebecca Schöber, Karl Fengler, Florian Schlotter, Sara Bombace, Paula Sagmeister, Maximilian von Roeder, Tobias Kister, Matthias Gutberlet, Holger Thiele, Karl‐Philipp Rommel, Philipp Lurz
AimsThe aim of this study was to assess the pathophysiological implications of severe tricuspid regurgitation (TR) in patients with heart failure with preserved ejection fraction (HFpEF) by using tricuspid transcatheter edge‐to‐edge repair (T‐TEER) as a model of right ventricular (RV) volume overload relief.Methods and resultsThis prospective interventional single arm trial (NCT04782908) included patients
-
Sex-related similarities and differences in responses to heart failure therapies Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-08 Janice Y. Chyou, Hailun Qin, Javed Butler, Adriaan A. Voors, Carolyn S. P. Lam
-
Cardiac memory: a phenomenon with important clinical implications Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-07 Rebecca J. Gilchrist
Rebecca Gilchrist discusses the study that demonstrated the long-term modulation of ventricular repolarization by the sequence of electrical activation in the human heart and established the concept of cardiac memory.
-
Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-07 Justin Ezekowitz, Wendimagegn Alemayehu, Frank Edelmann, Piotr Ponikowski, Carolyn S.P. Lam, Christopher M. O'Connor, Javed Butler, Stefano Corda, Ciaran J. McMullan, Cynthia M. Westerhout, Adriaan A. Voors, Robert J. Mentz, Paul W. Armstrong
-
Rewiring Endothelial Sphingolipid Metabolism to Favor S1P Over Ceramide Protects From Coronary Atherosclerosis Circ. Res. (IF 20.1) Pub Date : 2024-03-08 Onorina Laura Manzo, Jasmine Nour, Linda Sasset, Alice Marino, Luisa Rubinelli, Sailesh Palikhe, Martina Smimmo, Yang Hu, Maria Rosaria Bucci, Alain Borczuk, Olivier Elemento, Julie K. Freed, Giuseppe Danilo Norata, Annarita Di Lorenzo
Background:Growing evidence correlated changes in bioactive sphingolipids, particularly S1P (sphingosine-1-phosphate) and ceramides, with coronary artery diseases. Furthermore, specific plasma ceramide species can predict major cardiovascular events. Dysfunction of the endothelium lining lesion-prone areas plays a pivotal role in atherosclerosis. Yet, how sphingolipid metabolism and signaling change
-
CNP Ameliorates Macrophage Inflammatory Response and Atherosclerosis Circ. Res. (IF 20.1) Pub Date : 2024-03-08 Qiankun Bao, Bangying Zhang, Lu Zhou, Qian Yang, Xiaofeng Mu, Xing Liu, Shiying Zhang, Meng Yuan, Yue Zhang, Jingjin Che, Wen Wei, Tong Liu, Guangping Li, Jinlong He
BACKGROUND:CNP (C-type natriuretic peptide), an endogenous short peptide in the natriuretic peptide family, has emerged as an important regulator to govern vascular homeostasis. However, its role in the development of atherosclerosis remains unclear. This study aimed to investigate the impact of CNP on the progression of atherosclerotic plaques and elucidate its underlying mechanisms.METHODS:Plasma
-
Thrombocytopenia Independently Leads to Changes in Monocyte Immune Function Circ. Res. (IF 20.1) Pub Date : 2024-03-08 Chen Li, Sara K. Ture, Benjamin Nieves-Lopez, Sara K. Blick-Nitko, Preeti Maurya, Alison C. Livada, Tyler J. Stahl, Minsoo Kim, Anthony P. Pietropaoli, Craig N. Morrell
BACKGROUND:While platelets have well-studied hemostatic functions, platelets are immune cells that circulate at the interface between the vascular wall and white blood cells. The physiological implications of these constant transient interactions are poorly understood. Activated platelets induce and amplify immune responses, but platelets may also maintain immune homeostasis in healthy conditions,
-
Changes in right ventricular function and clinical outcomes following tricuspid transcatheter edge‐to‐edge repair Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-08 Tetsu Tanaka, Atsushi Sugiura, Refik Kavsur, Can Öztürk, Nihal Wilde, Sebastian Zimmer, Georg Nickenig, Marcel Weber, Johanna Vogelhuber
-
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits Cardiovasc. Res. (IF 10.8) Pub Date : 2024-03-08 Alberto Preda, Fabrizio Montecucco, Federico Carbone, Giovanni G Camici, Thomas F Lüscher, Simon Kraler, Luca Liberale
An increasing number of individuals is at high risk of type 2 diabetes (T2D) and its cardiovascular complications, including heart failure (HF), chronic kidney disease (CKD), and premature death. The sodium-glucose cotransporter-2 (SGLT2) protein sits in the proximal tubule of human nephrons to regulate glucose reabsorption, and its inhibition by gliflozins represents the cornerstone of contemporary
-
Smooth muscle cell-specific MMP-3 deletion reduces osteogenic transformation and medial artery calcification Cardiovasc. Res. (IF 10.8) Pub Date : 2024-03-08 Yangzhouyun Xie, Tonghui Lin, Ying Jin, Alexa G Berezowitz, Xue-Lin Wang, Jinny Lu, Yujun Cai, Raul J Guzman
Aims Vascular calcification is highly prevalent in atherosclerosis, diabetes, and chronic kidney disease. It is associated with increased morbidity and mortality in patients with cardiovascular disease. Matrix metalloproteinase 3 (MMP-3), also known as stromelysin-1, is part of the large matrix metalloproteinase family. It can degrade extracellular matrix components of the arterial wall including elastin
-
Status and Future Directions for Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease With and Without Pulmonary Hypertension: A Scientific Statement From the American Heart Association Circulation (IF 37.8) Pub Date : 2024-03-07 Vikas Aggarwal, Jay Giri, Scott H. Visovatti, Ehtisham Mahmud, Hiromi Matsubara, Michael Madani, Frances Rogers, Deepa Gopalan, Kenneth Rosenfield, Vallerie V. McLaughlin, on behalf of the American Heart Association Council on Clinical Cardiology, Council on Peripheral Vascular Disease, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, and Council on Cardiovascular and Stroke
Balloon pulmonary angioplasty continues to gain traction as a treatment option for patients with chronic thromboembolic pulmonary disease with and without pulmonary hypertension. Recent European Society of Cardiology guidelines on pulmonary hypertension now give balloon pulmonary angioplasty a Class 1 recommendation for inoperable and residual chronic thromboembolic pulmonary hypertension. Not surprisingly
-
Weight telemonitoring of heart failure versus standard of care in a real‐world setting: Results on mortality and hospitalizations in a 6‐month nationwide matched cohort study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-07 François Roubille, Grégoire Mercier, Guila Lancman, Hélène Pasche, Sarah Alami, Cécile Delval, Antoine Bessou, Jade Vadel, Amayelle Rey, Stéphanie Duret, Emilie Abraham, Gilles Chatellier, Isabelle Durand Zaleski
-
Blood pressure and intensive treatment up‐titration after acute heart failure hospitalization: Insights from the STRONG‐HF trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-06 Matteo Pagnesi, Oscar Alberto Gomez Vilamajó, Alejandro Meiriño, Carlos Alberto Dumont, Alexandre Mebazaa, Beth Davison, Marianna Adamo, Mattia Arrigo, Marianela Barros, Jan Biegus, Jelena Celutkiene, Kamilė Čerlinskaitė‐Bajorė, Ovidiu Chioncel, Alain Cohen‐Solal, Albertino Damasceno, Rafael Diaz, Christopher Edwards, Gerasimos Filippatos, Etienne Gayat, Antoine Kimmoun, Carolyn S.P. Lam, Maria Novosadova
AimsA high‐intensity care (HIC) strategy with rapid guideline‐directed medical therapy (GDMT) up‐titration and close follow‐up visits improved outcomes, compared to usual care (UC), in patients recently hospitalized for acute heart failure (AHF). Hypotension is a major limitation to GDMT implementation. We aimed to assess the impact of baseline systolic blood pressure (SBP) on the effects of HIC versus
-
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence Eur. Heart J. (IF 39.3) Pub Date : 2024-03-05 Nabil V Sayour, Ágnes M Paál, Pietro Ameri, Wouter C Meijers, Giorgio Minotti, Ioanna Andreadou, Antonella Lombardo, Massimiliano Camilli, Heinz Drexel, Erik Lerkevang Grove, Gheorghe Andrei Dan, Andreea Ivanescu, Anne Grete Semb, Gianluigi Savarese, Dobromir Dobrev, Filippo Crea, Juan-Carlos Kaski, Rudolf A de Boer, Péter Ferdinandy, Zoltán V Varga
Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of HF. While both the prevention and treatment of new-onset HF in patients with cancer have been investigated extensively, less is known about the prevention and treatment of new-onset cancer in patients with HF, and whether and how guideline-directed medical therapy
-
Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment Eur. Heart J. (IF 39.3) Pub Date : 2024-03-05 Denisa Muraru, Luigi P Badano, Rebecca T Hahn, Roberto M Lang, Victoria Delgado, Nina C Wunderlich, Erwan Donal, Maurizio Taramasso, Alison Duncan, Philipp Lurz, Tom De Potter, José L Zamorano Gómez, Jeroen J Bax, Ralph Stephan von Bardeleben, Maurice Enriquez-Sarano, Francesco Maisano, Fabien Praz, Marta Sitges
Atrial secondary tricuspid regurgitation (A-STR) is a distinct phenotype of secondary tricuspid regurgitation with predominant dilation of the right atrium and normal right and left ventricular function. Atrial secondary tricuspid regurgitation occurs most commonly in elderly women with atrial fibrillation and in heart failure with preserved ejection fraction in sinus rhythm. In A-STR, the main mechanism
-
Characterization of Vascular Niche in Systemic Sclerosis by Spatial Proteomics Circ. Res. (IF 20.1) Pub Date : 2024-03-05 Aleix Rius Rigau, Yi-Nan Li, Alexandru-Emil Matei, Andrea-Hermina Györfi, Peter-Martin Bruch, Sarah Koziel, Veda Devakumar, Armando Gabrielli, Alexander Kreuter, Jiucun Wang, Sascha Dietrich, Georg Schett, Jörg H.W. Distler, Minrui Liang
BACKGROUND:Systemic sclerosis (SSc) is a connective tissue disease that can serve as a model to study vascular changes in response to inflammation, autoimmunity, and fibrotic remodeling. Although microvascular changes are the earliest histopathologic manifestation of SSc, the vascular pathophysiology remains poorly understood.OBJECTIVE:We applied spatial proteomic approaches to deconvolute the heterogeneity
-
‘Micro’‐managing heart failure: Restoring that which was lost in translation Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 A. Mark Richards, Peipei Wang, Lee Lee Wong
-
Iron replacement therapy in heart failure: Contextualizing the results of the HEART‐FID trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 Javed Butler, Robert J. Mentz, Adrian F. Hernandez
-
Association of diabetes‐specific heart failure risk score with presence of subclinical cardiomyopathy among individuals with diabetes: A prospective study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 Zainali S. Chunawala, Neil Keshvani, Matthew W. Segar, Kershaw V. Patel, Muhammad Shariq Usman, Vinayak Subramanian, Viraj Raygor, Alvin Chandra, Muhammad Shahzeb Khan, Ambarish Pandey
-
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 João Pedro Ferreira, Milton Packer, Naveed Sattar, Javed Butler, Stuart J. Pocock, Stefan D. Anker, Sandra González Maldonado, Marina Panova‐Noeva, Mikhail Sumin, Serge Masson, Faiez Zannad, James L. Januzzi
-
Effect of long‐term tafamidis treatment on health‐related quality of life in patients with transthyretin amyloid cardiomyopathy Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 Martha Grogan, Margot K. Davis, Maria G. Crespo‐Leiro, Marla B. Sultan, Balarama Gundapaneni, Franca Stedile Angeli, Mazen Hanna
AimsTo evaluate the effect of long‐term tafamidis treatment on health‐related quality of life (HRQoL) in patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension (LTE) study.Methods and resultsWe examined change from baseline in Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ‐OS)
-
Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR‐Preserved analysis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 João Pedro Ferreira, Faiez Zannad, Milton Packer, Gerasimos Filippatos, Stuart J. Pocock, Francisco Vasques‐Nóvoa, Michael Böhm, Javed Butler, Stefan Anker
-
Prevalence of wild‐type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo‐VIP‐HF study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-03-05 Alwin Tubben, Hendrea S.A. Tingen, Niek H.J. Prakken, Vanessa P.M. van Empel, Thomas M. Gorter, Laura M.G. Meems, Olivier C. Manintveld, Michiel Rienstra, Robert G. Tieleman, Andor W.J.M. Glaudemans, Dirk J. van Veldhuisen, Riemer H.J.A. Slart, Hans L.A. Nienhuis, Peter van der Meer
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underrecognized fatal disease characterized by extracellular deposition of misfolded transthyretin proteins causing heart failure (HF).1 Previous studies on ATTR-CM prevalence have mostly been performed retrospectively and in selected cohorts.2-4 A recent community screening study found that ATTR-CM, defined in this study by a Perugini grade ≥2 out
-
The electrophysiologic effects of KCNQ1 extend beyond expression of IKs: evidence from genetic and pharmacologic block Cardiovasc. Res. (IF 10.8) Pub Date : 2024-03-05 Yuko Wada, Lili Wang, Lynn D Hall, Tao Yang, Laura L Short, Joseph F Solus, Andrew M Glazer, Dan M Roden
Aims While variants in KCNQ1 are the commonest cause of the congenital long QT syndrome, we and others find only a small IKs in cardiomyocytes from human induced pluripotent stem cells (iPSC-CMs) or human ventricular myocytes. Methods and Results We studied population control iPSC-CMs and iPSC-CMs from a patient with Jervell and Lange-Nielsen (JLN) syndrome due to compound heterozygous loss of function
-
Metabolic product of excess niacin is linked to increased risk of cardiovascular events Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-04 Gregory B. Lim
A metabolic product of excess niacin promotes vascular inflammation in preclinical models and is associated with increased rates of major adverse cardiovascular events in humans.
-
Role of CD4+ T-cells for regulating splenic myelopoiesis and monocyte differentiation after experimental myocardial infarction Basic Res. Cardiol. (IF 9.5) Pub Date : 2024-03-04 Nadine Gladow, Claudia Hollmann, Johannes Weirather, Xin Ding, Matthias Burkard, Sabrina Uehlein, Richa Bharti, Konrad Förstner, Thomas Kerkau, Niklas Beyersdorf, Stefan Frantz, Gustavo Ramos, Ulrich Hofmann
-
Toward Heart-Healthy and Sustainable Cities: A Policy Statement From the American Heart Association Circulation (IF 37.8) Pub Date : 2024-03-04 Sanjay Rajagopalan, Anu Ramaswami, Aruni Bhatnagar, Robert D. Brook, Mark Fenton, Christopher Gardner, Roni Neff, Armistead G. Russell, Karen C. Seto, Laurie P. Whitsel, on behalf of the American Heart Association Council on Hypertension, Council on Lifestyle and Cardiometabolic Health, Council on Peripheral Vascular Disease, Council on Lifelong Congenital Heart Disease and Heart Health in the Young
Nearly 56% of the global population lives in cities, with this number expected to increase to 6.6 billion or >70% of the world’s population by 2050. Given that cardiometabolic diseases are the leading causes of morbidity and mortality in people living in urban areas, transforming cities and urban provisioning systems (or urban systems) toward health, equity, and economic productivity can enable the
-
Crosstalk of human coronary perivascular adipose-derived stem cells with vascular cells: role of tissue factor Basic Res. Cardiol. (IF 9.5) Pub Date : 2024-03-02 Gemma Arderiu, Maria Teresa Bejar, Anna Civit-Urgell, Esther Peña, Lina Badimon
-
Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry Eur. Heart J. (IF 39.3) Pub Date : 2024-03-01 Mikhael F El-Chami, Christophe Garweg, Nicolas Clementy, Faisal Al-Samadi, Saverio Iacopino, Jose Luis Martinez-Sande, Paul R Roberts, Claudio Tondo, Jens Brock Johansen, Xavier Vinolas-Prat, Yong-Mei Cha, Eric Grubman, Pierre Bordachar, Kurt Stromberg, Dedra H Fagan, Jonathan P Piccini
Background and Aims Prior reports have demonstrated a favourable safety and efficacy profile of the Micra leadless pacemaker over mid-term follow-up; however, long-term outcomes in real-world clinical practice remain unknown. Updated performance of the Micra VR leadless pacemaker through five years from the worldwide post-approval registry (PAR) was assessed. Methods All Micra PAR patients undergoing
-
Transcatheter treatment of the tricuspid valve: current status and perspectives Eur. Heart J. (IF 39.3) Pub Date : 2024-03-01 Francesco Maisano, Rebecca Hahn, Paul Sorajja, Fabien Praz, Philipp Lurz
Transcatheter tricuspid valve interventions (TTVI) are emerging as alternatives to surgery in high-risk patients with isolated or concomitant tricuspid regurgitation. The development of new minimally invasive solutions potentially more adapted to this largely undertreated population of patients, has fuelled the interest for the tricuspid valve. Growing evidence and new concepts have contributed to
-
Kidney replacement therapy: trends in incidence, treatment, and outcomes of myocardial infarction and stroke in a nationwide Scottish study Eur. Heart J. (IF 39.3) Pub Date : 2024-03-01 Peter J Gallacher, David Yeung, Samira Bell, Anoop S V Shah, Nicholas L Mills, Neeraj Dhaun
Background and Aims Patients with kidney failure have a higher risk of cardiovascular disease compared with the general population. Whilst temporal trends of myocardial infarction and stroke are declining in the general population, these have not been evaluated in patients with kidney failure. This study aimed to describe national trends in the incidence, treatment, and outcomes of myocardial infarction
-
Rheumatoid arthritis and cardiovascular complications during delivery: a United States inpatient analysis Eur. Heart J. (IF 39.3) Pub Date : 2024-03-01 Salman Zahid, Mohamed S Mohamed, Aardra Rajendran, Anum S Minhas, Muhammad Zia Khan, Noreen T Nazir, Anthony J Ocon, Brittany N Weber, Ijeoma Isiadinso, Erin D Michos
Background and Aims Persons with rheumatoid arthritis (RA) have an increased risk of obstetric-associated complications, as well as long-term cardiovascular (CV) risk. Hence, the aim was to evaluate the association of RA with acute CV complications during delivery admissions. Methods Data from the National Inpatient Sample (2004–2019) were queried utilizing ICD-9 or ICD-10 codes to identify delivery